ALLO advances cema-cel and ALLO-329 with strong interim data
ALLO says its cema-cel and ALLO-329 programs are advancing with strong interim data and broader MRD testing adoption. Commercial launch planning is underway, and its financial runway extends into 2029.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.